A three-year-old boy from California, Oliver Chu, has amazed medical experts after becoming the first person globally with Hunter syndrome to receive a pioneering gene therapy designed to halt the disease’s progression. The rare, inherited disorder, also known as MPS II, gradually damages the body and brain, often leading to death before the age of 20 in severe cases.

Oliver’s treatment represents a breakthrough: scientists in Manchester modified his own cells to produce an enzyme his body could not previously make. A year after the procedure, he is showing near-normal development, including cognitive and motor improvements, offering hope to families affected by this devastating condition.

Hunter Syndrome: Rare and Devastating

Hunter syndrome is caused by a genetic mutation that prevents the production of iduronate-2-sulfatase (IDS), an enzyme critical for breaking down large sugar molecules in cells. Without IDS, these molecules accumulate, causing damage to organs, bones, joints, and the nervous system. Symptoms typically appear around age two, including stiff limbs, short stature, delayed speech, and progressive cognitive decline. The condition almost exclusively affects boys, with an incidence of approximately one in 100,000 male births.

Until now, treatment options were limited. Enzyme replacement therapy, such as Elaprase, can slow some physical effects but does not cross the blood-brain barrier and cannot prevent cognitive decline. Treatments cost around £300,000 per patient annually.

The Gene Therapy Process

Oliver’s therapy began in December 2024 at the Royal Manchester Children’s Hospital. Doctors removed a portion of his stem cells using a machine designed for precise collection. These cells were then sent to Great Ormond Street Hospital in London for genetic modification.

In the lab, scientists inserted a functional copy of the IDS gene into a harmless virus, which served as a delivery mechanism. The virus then transferred the gene into Oliver’s stem cells. Importantly, the gene was modified to allow the enzyme to cross the blood-brain barrier, addressing both physical and neurological symptoms.

By February 2025, the gene-modified stem cells were returned to Manchester for infusion. Oliver received two infusions via a catheter in his chest, each containing approximately 125 million modified stem cells. The procedure was completed in minutes, and Oliver remained calm, watching cartoons during the treatment.

Early Signs of Improvement

By May 2025, follow-up testing indicated significant progress. Oliver displayed improved mobility, speech, and social engagement. Crucially, he no longer required weekly enzyme infusions, as his body had begun producing the missing IDS enzyme naturally.

His mother, Jingru, described the changes as “amazing,” while his father, Ricky, emphasized the rapid improvement in cognitive and physical abilities. Oliver’s older brother, Skyler, also diagnosed with Hunter syndrome, continues to receive conventional infusions but is not yet eligible for gene therapy targeting the brain.

Ongoing Monitoring and Future Plans

Oliver will continue regular check-ups every three months to monitor his enzyme production and neurological development. The clinical trial includes five boys from the US, Europe, and Australia, all of whom will be observed for at least two years. If successful, researchers plan to partner with biotech companies to make the therapy widely available.

Professor Simon Jones, co-leader of the trial, stressed cautious optimism: “Things are as good as they could be at this point, but we need to monitor carefully. We are encouraged by his progress in learning, mobility, and overall health.”

A Trial That Nearly Never Happened

The gene therapy originated from more than 15 years of research led by Professor Brian Bigger at the University of Manchester. Initially, a partnership with US biotech Avrobio faced setbacks due to poor results in a separate gene therapy trial and funding shortages, putting the first-in-human trial in jeopardy.

British charity LifeArc intervened with £2.5 million in funding, allowing the trial to proceed. Dr Sam Barrell, CEO of LifeArc, highlighted the challenges faced by patients with rare diseases, noting that 95% of such conditions have no effective treatments.

Hope for Families Affected by Hunter Syndrome

For the Chu family, the successful gene therapy has transformed daily life. Oliver now produces the missing enzyme, enjoys improved mobility, and engages fully with his surroundings. His parents hope Skyler may one day benefit from a similar treatment.

Ricky Chu reflected on the journey: “I would walk to the end of the earth, backwards, forwards, upside down, barefoot, to make sure my kids have a better future.”

The trial represents a landmark achievement in gene therapy, with potential applications for other rare genetic disorders, including MPS I (Hurler syndrome) and MPS III (Sanfilippo syndrome). Oliver’s story underscores the promise of genetic medicine in changing the outlook for children with previously untreatable conditions.

Source: BBC – Boy with rare condition amazes doctors after world-first gene therapy

The post Three-Year-Old Thrives After World-First Gene Therapy for Rare Hunter Syndrome appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

A promising new drug, tavapadon, has shown significant potential in treating Parkinson’s disease, offering relief from motor symptoms like tremors, stiffness, and coordination issues—without the common side effects associated with current treatments.

In clinical trials, tavapadon—a once-daily pill—has proven to be effective for patients already taking at least 400 mg of levodopa a day. It specifically benefits those experiencing “motor fluctuations,” a situation where levodopa’s effects wear off, causing symptoms to resurface. Researchers found that tavapadon provided more sustained “on time” (periods when symptoms are controlled) while reducing “off time” (when symptoms return), without the typical negative side effects that often accompany levodopa.

Levodopa has long been the standard treatment for Parkinson’s, but it can come with a range of side effects such as sleep disorders, hallucinations, and impulse control issues. Tavapadon works by mimicking dopamine in the brain and targeting different dopamine receptors (D1/D5), which offers the same symptom relief as levodopa but with fewer adverse effects.

Dr. Hubert H. Fernandez, the lead study author from the Cleveland Clinic, expressed optimism about tavapadon’s potential: “It provides patients with another option to alleviate motor fluctuations in the moderate to advanced stages of Parkinson’s. This is a promising step forward for both patients and doctors.”

The clinical trial, called TEMPO 3, was a multi-center, pivotal study that measured various side effects such as excessive daytime sleepiness, weight gain, and blood pressure changes. Remarkably, the side effects from tavapadon were no worse than those experienced by patients receiving a placebo.

Dr. Fernandez cautioned that while the results are promising, this study was short-term, and further long-term research is needed to fully confirm the drug’s benefits. Nonetheless, he remains hopeful, saying, “We’re very encouraged by these preliminary findings. Whether used at the beginning of treatment or alongside levodopa for more advanced cases, tavapadon represents a significant gain for Parkinson’s patients.”

For recently diagnosed patients with less severe symptoms, tavapadon may replace levodopa altogether, potentially reducing the need for frequent doses of the standard drug. This could minimize the risk of motor fluctuations and dyskinesia (involuntary movements), which are common side effects of levodopa use over time.

For more advanced Parkinson’s cases, tavapadon can be used in combination with levodopa, providing more consistent symptom relief without the typical side effects.

Parkinson’s disease is expected to become a global health crisis, with cases projected to increase to 25 million worldwide by 2050. The biggest surge is expected among people aged 80 and older, with the number of cases in that age group predicted to rise by 196%. This highlights the urgent need for improved treatments like tavapadon.

AbbVie, the pharmaceutical company behind tavapadon, is preparing to file for approval with the U.S. Food and Drug Administration (FDA). Once submitted, the FDA will review the application, which could lead to the drug being approved for widespread use. If approved, tavapadon could offer a new, more effective treatment option for people living with Parkinson’s disease, improving their quality of life and providing a much-needed alternative to existing therapies.

Dr. Mary Ann Picone, a medical director at Holy Name Medical Center, praised the trial results, calling the drug “very interesting and encouraging” for Parkinson’s patients. She highlighted that one of the major challenges of current Parkinson’s treatments is the wearing-off phenomenon, where the drug’s effects diminish over time, leading to “freezing” episodes and increased stiffness.

Tavapadon’s ability to target different dopamine receptors could extend the beneficial effects of treatment, offering patients more “on time” without the involuntary movements that often interfere with their ability to function. As Dr. Picone noted, this new therapy could be a game-changer in improving quality of life for those living with Parkinson’s.

As the long-term clinical trials continue, there’s growing hope that tavapadon will become a vital part of Parkinson’s treatment. With its potential to reduce motor symptoms and side effects, this new drug could offer a better, more sustainable treatment option for patients at every stage of the disease.

Stay tuned for further updates as the FDA review process moves forward, with the possibility of a new chapter in Parkinson’s disease treatment just around the corner.

Source: FOX News – New drug for Parkinson’s shown to be effective in clinical trials: ‘Very encouraged’

The post New Parkinson’s Drug Tavapadon Shows Promise in Clinical Trials appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Chinese scientists have made significant progress in fertility research by using stem cell transplantation to extend the reproductive lifespan in female monkeys. This breakthrough could provide new options for women struggling to conceive, especially as the average age for having children continues to rise.

The study, conducted by researchers from the Chinese Academy of Sciences and published in Cell Discovery, addresses the issue of ovarian aging, which naturally affects female fertility. As the ovaries age, they produce fewer eggs and hormones, leading to menopause and related health issues. Currently, there is no effective treatment to fully restore ovarian function.

Stem cells have shown promise in treating premature ovarian aging, so researchers investigated whether these treatments could benefit naturally aging ovaries. In the study, they transplanted M-cells—stem cells derived from human embryonic cells with strong immune and anti-inflammatory properties—into the ovaries of aging crab-eating macaques, a type of monkey with a reproductive aging pattern similar to humans.

The results were promising. The treated monkeys showed improved hormone levels, more active ovarian follicles, reduced ovarian fibrosis, and even healthier overall reproductive functions. One monkey even conceived and gave birth, highlighting the treatment’s potential.

With the average age of first-time mothers rising—27 in the United States, nearly 29 in Australia, and over 32 in South Korea—more women are experiencing fertility challenges as ovarian function begins to decline around their late 30s to mid-40s. In China, where the average age for first-time mothers is now over 27, regions like Shanghai see averages above 30.

Current treatments, like hormone replacement therapy, can help ease menopausal symptoms but carry risks such as heart disease, stroke, and breast cancer. Researchers aim to find safer, more effective treatments, especially given that ovarian aging can lead to serious conditions, including osteoporosis, cardiovascular disease, and neurodegenerative disorders.

The study also examined ovarian tissue samples from Chinese women in various age ranges. Findings showed a sharp decline in primordial follicle reserves by age 40, with reserves nearly exhausted by early 50s. But these remaining follicles could still potentially grow, supporting the idea of extending reproductive lifespan.

M-cell transplantation could be a safer and more effective approach to delay ovarian aging, as none of the treated monkeys showed signs of inflammation or other serious side effects. In comparison to untreated monkeys, the transplanted group showed improved hormone levels, follicle development, reduced fibrosis, and lower DNA damage.

The research team concluded that “M-cell transplantation is a feasible clinical strategy to alleviate physiological ovarian aging and extend fertility lifespan,” offering a new direction in fertility treatment that could improve quality of life for many women.

Source

Full Video

The post Chinese Scientists Discover Stem Cell Treatment to Combat Ovarian Aging appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Millions of teenagers in Africa are suffering from asthma with no formal diagnosis as the continent undergoes rapid urbanisation, researchers have found.

The study, published in the Lancet Child and Adolescent Health, involved 27,000 pupils from urban areas in Malawi, South Africa, Zimbabwe, Uganda, Ghana and Nigeria. It found more than 3,000 reported asthma symptoms, but only about 600 had a formal diagnosis.

Many of the children reported missing school or having their sleep disrupted by wheezing.

“If our data are generalisable, there are millions of adolescents with undiagnosed asthma symptoms in sub-Saharan Africa,” said Dr Gioia Mosler of Queen Mary University of London, the study’s research manager.

The team that led the study, whose research on the impact of pollution on lung health was instrumental in introducing the ultra low-emission zone (Ulez) in London, said there was an urgent need for medicines and diagnostic tests in the region.

Rates of asthma have increased in sub-Saharan Africa over the past few decades, a trend attributed to rapid urbanisation which exposes children to more risk factors such as air pollution. The climate crisis was also likely to have an impact, experts said.

The Achieving Control of Asthma in Children and Adolescents in Africa (Acacia) study recruited pupils aged between 12 and 14. Screening revealed that while 12% reported asthma symptoms, only 20% of that group had received a formal diagnosis of asthma.

Lung function tests suggested nearly half of undiagnosed participants with severe symptoms were “very likely” to have asthma.

Even among those who had received a formal diagnosis, about a third were not using any medicine to control their condition, according to the study.

Dr Rebecca Nantanda of Makerere University in Kampala, who led the research in Uganda, said: “Undiagnosed and poorly controlled asthma greatly impacts on the physical and psychosocial wellbeing of the affected children and their caregivers. The high burden of severe undiagnosed asthma revealed by the Acacia study requires urgent attention, including access to medicines and diagnostics.”

Prof Jonathan Grigg of Queen Mary University of London, said asthma was made worse by exposure to small particles of pollutants, with the impact of the climate crisis yet to become clear. “In some areas in sub-Saharan Africa, climate change is likely to result in increased exposure of these vulnerable children to dust and natural fires.

“On the other hand, climate change mitigation will, hopefully, reduce exposure to fossil fuel-derived particles in this region.

“The pharmaceutical industry has been hesitant to support asthma research and initiatives. For example, companies may feel that they cannot support research in countries where they do not intend to market their asthma product,” he said.

“Innovations such as handheld wheeze detectors and asthma clinics delivered at schools also have the potential to substantially reduce the burden of asthma.”

Source

The post Study Reveals Millions of African Teenagers Suffer from Undiagnosed Asthma appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.